CA2066751A1 - Controlled-release pharmaceutical composition for the oral use containing non steroidal anti-inflammatory drugs - Google Patents
Controlled-release pharmaceutical composition for the oral use containing non steroidal anti-inflammatory drugsInfo
- Publication number
- CA2066751A1 CA2066751A1 CA002066751A CA2066751A CA2066751A1 CA 2066751 A1 CA2066751 A1 CA 2066751A1 CA 002066751 A CA002066751 A CA 002066751A CA 2066751 A CA2066751 A CA 2066751A CA 2066751 A1 CA2066751 A1 CA 2066751A1
- Authority
- CA
- Canada
- Prior art keywords
- release
- pharmaceutical composition
- units
- controlled
- sub
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- 238000013270 controlled release Methods 0.000 title claims abstract description 13
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 7
- 239000007903 gelatin capsule Substances 0.000 claims abstract description 4
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 7
- 229960000991 ketoprofen Drugs 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000008119 colloidal silica Substances 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 108010001267 Protein Subunits Proteins 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 235000019759 Maize starch Nutrition 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- UJVBZCCNLAAMOV-UHFFFAOYSA-N 2h-1,2-benzothiazine Chemical compound C1=CC=C2C=CNSC2=C1 UJVBZCCNLAAMOV-UHFFFAOYSA-N 0.000 description 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229950005175 sudoxicam Drugs 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT20943A/90 | 1990-07-13 | ||
| IT02094390A IT1243341B (it) | 1990-07-13 | 1990-07-13 | Composizione farmaceutica per uso orale a rilascio modificato di antiinfiammatori non steroidei |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2066751A1 true CA2066751A1 (en) | 1992-01-14 |
Family
ID=11174413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002066751A Abandoned CA2066751A1 (en) | 1990-07-13 | 1991-07-04 | Controlled-release pharmaceutical composition for the oral use containing non steroidal anti-inflammatory drugs |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0491911A1 (enrdf_load_stackoverflow) |
| AU (1) | AU8186291A (enrdf_load_stackoverflow) |
| CA (1) | CA2066751A1 (enrdf_load_stackoverflow) |
| ES (1) | ES2043567T1 (enrdf_load_stackoverflow) |
| GR (1) | GR930300020T1 (enrdf_load_stackoverflow) |
| IT (1) | IT1243341B (enrdf_load_stackoverflow) |
| WO (1) | WO1992000730A1 (enrdf_load_stackoverflow) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993017673A1 (en) * | 1992-03-03 | 1993-09-16 | Top Gold Pty., Limited | Sustained release analgesics |
| US5922722A (en) * | 1996-11-12 | 1999-07-13 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
| DE19718012C1 (de) * | 1997-04-29 | 1998-10-08 | Jenapharm Gmbh | Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe |
| DE19901683B4 (de) * | 1999-01-18 | 2005-07-21 | Grünenthal GmbH | Analgetikum mit kontrollierter Wirkstofffreisetzung |
| EP2070520A1 (en) * | 2007-12-11 | 2009-06-17 | LEK Pharmaceuticals D.D. | Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2021147A1 (de) * | 1970-04-30 | 1971-11-11 | Christian Brunnengraeber Chem | Kapsel mit einer Fuellung von Pharmazeutika |
| US4773907A (en) * | 1982-12-20 | 1988-09-27 | Alza Corporation | Primary delivery system comprising secondary dosage form |
| GB2176999B (en) * | 1985-06-22 | 1989-07-12 | Stanley Stewart Davis | Sustained release medicament |
| IT1230576B (it) * | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon |
-
1990
- 1990-07-13 IT IT02094390A patent/IT1243341B/it active IP Right Grant
-
1991
- 1991-07-04 WO PCT/EP1991/001246 patent/WO1992000730A1/en not_active Application Discontinuation
- 1991-07-04 AU AU81862/91A patent/AU8186291A/en not_active Abandoned
- 1991-07-04 ES ES91912626T patent/ES2043567T1/es active Pending
- 1991-07-04 CA CA002066751A patent/CA2066751A1/en not_active Abandoned
- 1991-07-04 EP EP19910912626 patent/EP0491911A1/en not_active Withdrawn
-
1993
- 1993-04-28 GR GR930300020T patent/GR930300020T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU8186291A (en) | 1992-02-04 |
| EP0491911A1 (en) | 1992-07-01 |
| IT1243341B (it) | 1994-06-10 |
| IT9020943A1 (it) | 1992-01-13 |
| IT9020943A0 (it) | 1990-07-13 |
| WO1992000730A1 (en) | 1992-01-23 |
| GR930300020T1 (enrdf_load_stackoverflow) | 1993-04-28 |
| ES2043567T1 (es) | 1994-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4913906A (en) | Novel controlled release dosage form of valproic acid | |
| EP0324981B1 (en) | New galenic formulations with programmed release | |
| CA1148084A (en) | Dipyridamol sustained release forms and processes for the preparation thereof | |
| AU600765B2 (en) | Controlled release hydromorphone composition | |
| CA1264296A (en) | Formulations providing three distinct releases | |
| US5520931A (en) | Controlled release morphine preparation | |
| US4927640A (en) | Controlled release beads having glass or silicon dioxide core | |
| JP4012689B2 (ja) | 新規徐放性経口製剤 | |
| US4728513A (en) | Granular delayed-release form of pharmaceutically active substances | |
| US5472704A (en) | Pharmaceutical controlled-release composition with bioadhesive properties | |
| US4851226A (en) | Chewable medicament tablet containing means for taste masking | |
| US4794001A (en) | Formulations providing three distinct releases | |
| US4904476A (en) | Formulations providing three distinct releases | |
| JP2916978B2 (ja) | 放出開始制御型製剤 | |
| EP0255404B1 (en) | Sustained release ibuprofen formulation | |
| EP0213083A2 (en) | Controlled release tablet | |
| HU226670B1 (en) | Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance | |
| EP0418596A2 (en) | Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form. | |
| GB2128088A (en) | Oral mopidamol preparations | |
| JPS62106011A (ja) | 徐放性錠剤 | |
| RU2001111887A (ru) | Композиция в виде множества частиц с модифицированным высвобождением | |
| EP0662824A1 (en) | Article containing a core and a coating having a non constant thickness | |
| JPH0772129B2 (ja) | 持続放出性複合単位製剤 | |
| ES2338536T3 (es) | Comprimido farmaceutico de liberacion extendida de metformina. | |
| US20030224045A1 (en) | Combination immediate release sustained release levodopa/carbidopa dosage forms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |